RE: Ichor25 Feb 2023 07:52
TF .. look back through the list of RNS’s .. I just did, and can’t see any reason to suggest they don’t keep shareholders informed?
Empty.. if it is Ichor exiting, I’d actually like to thank them for the pivotal role they have had in getting scancell to where it is now .. the Scib1 phase 1/2 trial produced some fantastic results .. it’s just a shame the fda never sanctioned the trial in the US.
The move to needle free delivery for immunobody vaccines was a big risk but looks to be proving a good one!
Scancell is a tiny fellowship of scientists trying to solve problems in ways nobody else has tried yet.
The focus for scancell should always be on the science and on the people on the other end of the delivery device and certainly not me , a shareholder.
They succeed, I succeed .. simple as that.
Take care all..